Cross Bridge | BENEFACTORS
page-template,page-template-full_width,page-template-full_width-php,page,page-id-13671,ajax_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-1.0.0,qode-theme-ver-10.1.1,wpb-js-composer js-comp-ver-5.0.1,vc_responsive


CrossBridge aligns the interests of all stakeholders in the challenge of identifying and treating chronic inflammatory  diseases – and assures much needed transparency in a healthcare system focused on Value-Based Care.


Increased application of  “Window of Opportunity” treatment and more efficient selection of appropriate treatment.

Enhanced care coordination between primary physician and specialist (rheumatologist, gastroenterologist, neurologist).

Treatment information for shared decision making.

Better outcomes.

Physicians and Practices

CrossBridge becomes a single, unbiased source of evidence-based treatments, supported by identified medical authorities and peer-reviewed literature … a robust solution to support decision-making.

Decision support at the time of clinical prescribing – at no cost to the practice.

For each treatment option in the CrossBridge EBML, prescribers can view cost, clinical benefits, toxicities and outcomes targeted to stage of disease.

Increased probability of beginning proper treatment in the “Window of Opportunity”.

Maximum administration efficiency, including pre-auths at time of prescription. (CrossBridge integrates easily into any EMR.)

Specialty physicians can monitor pre-auths, including treatment deviations requiring medically justified variance from payers.

Enhanced care coordination/improved performance in primary care-driven Accountable Care Organizations (ACOs).

Equitable compensation in a Value-Based Care environment – transparent reimbursement.

Payers and Self-Insured Employers

All of the benefits to Patients and Payers manifest as better outcomes for chronic inflammatory diseases, justified reimbursements, lower costs.

Absolute control over drug spend…one of the single-largest factors in the treatment of chronic inflammatory diseases.

Minimization of administrative costs/maximization of efficiency for payers and Third-Party Administrators (TPAs).

Better outcomes.